CrystalGenomics Inc Asset Resilience Ratio
CrystalGenomics Inc asset resilience ratio. CrystalGenomics Inc (083790) has an Asset Resilience Ratio of 3.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 083790 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CrystalGenomics Inc (2011–2024)
Asset resilience ratio of CrystalGenomics Inc from 2011 to 2024. This chart shows how CrystalGenomics Inc's Asset Resilience Ratio has changed over time. Read CrystalGenomics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CrystalGenomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CrystalGenomics Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩7.74 Billion | 3.65% |
| Total Liquid Assets | ₩7.74 Billion | 3.65% |
Asset Resilience Insights
- Limited Liquidity: CrystalGenomics Inc maintains only 3.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CrystalGenomics Inc Industry Peers by Asset Resilience Ratio
Compare CrystalGenomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
CrystalGenomics Inc Asset Resilience Ratio by Year (2011–2024)
CrystalGenomics Inc asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for CrystalGenomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.52% | ₩53.43 Billion ≈ $36.21 Million |
₩260.47 Billion ≈ $176.51 Million |
+8.83pp |
| 2023-12-31 | 11.68% | ₩28.40 Billion ≈ $19.25 Million |
₩243.12 Billion ≈ $164.76 Million |
-13.71pp |
| 2022-12-31 | 25.39% | ₩81.92 Billion ≈ $55.51 Million |
₩322.61 Billion ≈ $218.63 Million |
-11.40pp |
| 2021-12-31 | 36.79% | ₩122.50 Billion ≈ $83.02 Million |
₩332.93 Billion ≈ $225.62 Million |
-7.11pp |
| 2020-12-31 | 43.90% | ₩139.15 Billion ≈ $94.30 Million |
₩316.96 Billion ≈ $214.80 Million |
+4.71pp |
| 2019-12-31 | 39.19% | ₩148.59 Billion ≈ $100.70 Million |
₩379.19 Billion ≈ $256.97 Million |
+21.66pp |
| 2018-12-31 | 17.53% | ₩45.03 Billion ≈ $30.52 Million |
₩256.92 Billion ≈ $174.11 Million |
-6.45pp |
| 2017-12-31 | 23.98% | ₩28.64 Billion ≈ $19.41 Million |
₩119.47 Billion ≈ $80.96 Million |
+2.87pp |
| 2016-12-31 | 21.10% | ₩27.15 Billion ≈ $18.40 Million |
₩128.67 Billion ≈ $87.20 Million |
+20.03pp |
| 2015-12-31 | 1.07% | ₩1.37 Billion ≈ $925.73K |
₩127.28 Billion ≈ $86.26 Million |
+0.31pp |
| 2014-12-31 | 0.76% | ₩808.97 Million ≈ $548.23K |
₩106.05 Billion ≈ $71.87 Million |
-0.73pp |
| 2013-12-31 | 1.49% | ₩1.33 Billion ≈ $898.43K |
₩88.77 Billion ≈ $60.16 Million |
-10.00pp |
| 2012-12-31 | 11.50% | ₩6.27 Billion ≈ $4.25 Million |
₩54.56 Billion ≈ $36.97 Million |
-7.78pp |
| 2011-12-31 | 19.28% | ₩12.14 Billion ≈ $8.22 Million |
₩62.96 Billion ≈ $42.67 Million |
-- |
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more